Johnson & Johnson and AbbVie subsidiary co-commercialize IMBRUVICA
What happened
Johnson & Johnson has partnered with Pharmacyclics, a subsidiary of AbbVie, to co-commercialize the prescription medicine IMBRUVICA in the U.S. In fiscal 2025, Johnson & Johnson's Innovative Medicine segment generated $60.4 billion in sales, while its MedTech segment generated $33.8 billion.
From fool.com
Why it matters
The partnership involves Johnson & Johnson and AbbVie, two direct competitors in the biopharmaceutical sector. This co-commercialization allows Johnson & Johnson to gain market access and revenue share for IMBRUVICA.
From fool.com
Who's involved
- Johnson & JohnsonPartnering to co-commercialize IMBRUVICA
- AbbVieParent company of Pharmacyclics
- PharmacyclicsPartnering with Johnson & Johnson to co-commercialize IMBRUVICA
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- PharmacyclicsSpeculative
Pharmacyclics could gain revenue and market reach through the co-commercialization of IMBRUVICA.
- Johnson & JohnsonSpeculative
Johnson & Johnson may gain market access and revenue share by co-commercializing IMBRUVICA.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Pharmacyclics shares IMBRUVICA sales with Johnson & JohnsonPharmacyclics gains shared revenue and market reach from IMBRUVICA salesLikely
- JNJ's new partnership could bolster Legend Biotech's strategic standingJNJ's expanded commercial reach may strengthen strategic partnerships like Legend Biotech'sPossible
- JNJ and AbbVie co-commercialization intensifies competition for Eli LillyIncreased competition from JNJ and AbbVie may challenge Eli Lilly's market share.Possible
- JNJ and AbbVie's IMBRUVICA deal may increase pressure on PfizerIncreased competition from JNJ and AbbVie may pressure Pfizer's market share.Possible
Keep exploring
The entities involved
-
Johnson & Johnson
U.S multinational medical devices, pharmaceutical and consumer packaged goods manufacturer
-
AbbVie
pharmaceutical company
Related events
- AbbVie, Boehringer Ingelheim, and Pfizer were present at a clinical conference in Las Vegas.
- Iambic Therapeutics announced multiple new partnerships, including collaborations with Jazz Pharmaceuticals and AbbVie, and received backing from Qatar Investment Authority and Nvidia.
- A group of major pharmaceutical companies, including AbbVie, Bristol-Myers Squibb, Amgen, Pfizer, Moderna, and Merck, are noted as peers operating in the highly regulated pharmaceutical sector.
- AbbVie and Boehringer Ingelheim are engaging with financial advisory firms regarding potential deals and discussing M&A strategies in the competitive pharmaceutical market.
- AbbVie, Abbott Laboratories, and Johnson & Johnson were recommended as dividend stocks for retirees, operating in the healthcare sector.